Source-grounded facts extracted from ARS Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ARS Pharmaceuticals, Inc. reported first quarter of 2026 results: revenue $22.7 million, net income ($60.6 million), EPS ($0.61) per share basic and diluted.
“ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million”
Richard Lowenthal changed role as President at ARS Pharmaceuticals, Inc..
“Mr. Lowenthal previously served as President.”
Donn Casale was appointed as President at ARS Pharmaceuticals, Inc..
“appointed Donn Casale as the Company’s President effective as of the date he commences employment with the Company, which date is expected to be June 1, 2026.”
ARS Pharmaceuticals, Inc. reported financial results for quarter and year ended December 31, 2025.
“On March 9, 2026, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
ARS Pharmaceuticals, Inc. incurred term loan of first tranche (the “Term A Loan”) was advanced in the principal amount of $100.0 million with RA Capital Agency Services, LLC as Administrative Agent and Collateral Agent; affiliates of OMERS Administration Corporation and RA Capital Management, L.P. as lenders maturing five-year anniversary of the Closing Date.
“The first tranche (the “Term A Loan”) was advanced in the principal amount of $100.0 million on September 29, 2025 (“Closing Date”).”
ARS Pharmaceuticals, Inc. incurred term loan of up to $250.0 million of term loans with RA Capital Agency Services, LLC as Administrative Agent and Collateral Agent; affiliates of OMERS Administration Corporation and RA Capital Management, L.P. as lenders at 5.50% plus the greater of (i) three-month forward-looking term SOFR or (ii) 3.00 maturing five-year anniversary of the Closing Date.
“On September 29, 2025, ARS Pharmaceuticals, Inc. (the “Company”) and certain direct and indirect subsidiaries of the Company who may become a party thereto from time to time, as guarantors (the “Guarantors”), and ARS Pharmaceuticals Operations, Inc., a wholly owned subsidiary of the Company, as the borrower (the “Borrower” and, collectively with the Guarantors, the “Credit Parties”), entered into a credit agreement (the “Credit Agreement”) with RA Capital Agency Services, LLC (as the “Administrative Agent” and as the “Collateral Agent”), and affiliates of OMERS Administration Corporation and RA Capital Management, L.P., as lenders, and such other lenders from time to time party thereto (the “Lenders”), providing for up to $250.0 million of term loans from the Lenders to the Borrower (the “Term Loans”).”
ARS Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 9, 2024, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
ARS Pharmaceuticals, Inc. reported three and nine months ended September 30, 2023 results: net income Net loss was $14.9 million for the quarter ended September 30, 2023..
“ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
ARS Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.4 million for the quarter ended June 30, 2023..
“On August 10, 2023, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.”
ARS Pharmaceuticals, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.
“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
ARS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-27 meeting.
“Proposal 1: Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
ARS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income $15.0 million.
“Net loss was $15.0 million for the quarter ended March 31, 2023.”
ARS Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $34.7 million.
“Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.”
ARS Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $14.4 million.
“Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.”
ARS Pharmaceuticals, Inc. terminated License and Supply Agreement with Recordati Ireland, LTD. (effective 2023-02-22).
“On February 22, 2023, the Company entered into the Termination Agreement with Recordati, pursuant to which, among other things, the Company and Recordati agreed to terminate the License and Supply Agreement, effective immediately.”
ARS Pharmaceuticals, Inc. entered into Termination Agreement with Recordati Ireland, LTD. valued at €3.0 million (effective 2023-02-22).
“On February 22, 2023, ARS Pharmaceuticals, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Recordati Ireland, LTD. (“Recordati”), pursuant to which, among other things, the Company and Recordati agreed to terminate that certain License and Supply Agreement, dated September 21, 2020, by and between the Company and Recordati (the “License and Supply Agreement”).”
Brian T. Dorsey was appointed as Chief Operations Officer at ARS Pharmaceuticals, Inc..
“Effective as of December 6, 2022, ARS Pharmaceuticals, Inc. (the “Company”) appointed Brian T. Dorsey, MSc, as Chief Operations Officer of the Company.”
ARS Pharmaceuticals, Inc.: Silverback Therapeutics, Inc. changed its name to ARS Pharmaceuticals, Inc. via a charter amendment effective upon merger consummation (effective 2022-11-08).
“on November 8, 2022, Silverback filed the Charter Amendment changing its name from "Silverback Therapeutics, Inc." to "ARS Pharmaceuticals, Inc."”
ARS Pharmaceuticals, Inc. underwent a change of control involving ARS Pharmaceuticals, Inc. (closed 2022-11-08).
“On November 8, 2022, Silverback, Merger Sub and ARS Pharma consummated the transactions contemplated by the Merger Agreement”
Phillip Schneider was appointed as Class III Director at ARS Pharmaceuticals, Inc..
“Phillip Schneider 66 Class III Director”
Brenton L. Saunders was appointed as Class II Director at ARS Pharmaceuticals, Inc..
“Brenton L. Saunders 52 Class II Director”
Jonathan S. Leff was appointed as Class III Director at ARS Pharmaceuticals, Inc..
“Jonathan S. Leff 53 Class III Director”
Peter Kolchinsky was appointed as Class II Director at ARS Pharmaceuticals, Inc..
“Peter Kolchinsky, Ph.D. 46 Class II Director”
Michael Kelly was appointed as Class I Director at ARS Pharmaceuticals, Inc..
“Michael Kelly 57 Class I Director”
Rajeev Dadoo was appointed as Class I Director at ARS Pharmaceuticals, Inc..
“Rajeev Dadoo, Ph.D. 52 Class I Director”
Pratik Shah was appointed as Chair of the Board and Class I Director at ARS Pharmaceuticals, Inc..
“Pratik Shah, Ph.D. 52 Chair of the Board and Class I Director”
Justin Chakma was appointed as Chief Business Officer and Secretary at ARS Pharmaceuticals, Inc..
“Justin Chakma 33 Chief Business Officer and Secretary”
Eric Karas was appointed as Chief Commercial Officer at ARS Pharmaceuticals, Inc..
“Eric Karas 50 Chief Commercial Officer”
Sarina Tanimoto was appointed as Chief Medical Officer at ARS Pharmaceuticals, Inc..
“Sarina Tanimoto, M.D., M.B.A. 54 Chief Medical Officer”
Kathleen Scott was appointed as Chief Financial Officer at ARS Pharmaceuticals, Inc..
“Kathleen Scott 53 Chief Financial Officer”
Richard Lowenthal was appointed as Class II Director at ARS Pharmaceuticals, Inc..
“Pursuant to the terms of the Merger Agreement, each of (i) Mr. Lowenthal, Dr. Shah, Dr. Dadoo, Mr. Kelly, Dr. Kolchinsky, Mr. Leff, Mr. Saunders and Mr. Schneider were appointed to the board of directors of the Company as designees of ARS Pharma”
Richard Lowenthal was appointed as President and Chief Executive Officer at ARS Pharmaceuticals, Inc..
“Richard Lowenthal, M.S., MSEL 56 President, Chief Executive Officer and Class II Director”
Russ Hawkinson was terminated as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..
“each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.”
Jeffrey Pepe was terminated as Interim Chief Executive Officer, General Counsel and Corporate Secretary at ARS Pharmaceuticals, Inc..
“each of Jeffrey Pepe, Ph.D., J.D., the Company’s Interim Chief Executive Officer, General Counsel and Corporate Secretary, and Russ Hawkinson, the Company’s Interim Chief Financial Officer, were terminated in connection with the Company’s previously announced reduction in force.”
Jonathan Root resigned as Director at ARS Pharmaceuticals, Inc..
“each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger”
Andrew Powell resigned as Director at ARS Pharmaceuticals, Inc..
“each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger”
Maria Koehler resigned as Director at ARS Pharmaceuticals, Inc..
“each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger”
Robert Hershberg resigned as Director at ARS Pharmaceuticals, Inc..
“each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger”
Vicki L. Capps resigned as Director at ARS Pharmaceuticals, Inc..
“each of Vicki L. Capps, Robert Hershberg, M.D., Ph.D., Maria Koehler, M.D., Ph.D., Andrew Powell, J.D. and Jonathan Root, M.D. resigned from the Company’s board of directors and any respective committee membership of the Company’s board of directors, effective as of the consummation of the Merger”
ARS Pharmaceuticals, Inc. amended Second Amendment to the Agreement and Plan of Merger and Reorganization with Silverback Therapeutics, Inc., Sabre Merger Sub, Inc., ARS Pharmaceuticals, Inc. (effective 2022-10-25).
“On October 25, 2022, Silverback Therapeutics, Inc. (“Silverback”), Sabre Merger Sub, Inc. (“Merger Sub”) and ARS Pharmaceuticals, Inc. (“ARS Pharma”), entered into the Second Amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization, dated as of July 21, 2022, as amended on August 11, 2022 (the “Merger Agreement”), by and among Silverback, Merger Sub and ARS Pharma, pursuant to which the parties agreed to amend the Merger Agreement as follows:”
Russ Hawkinson was appointed as Interim Chief Financial Officer at ARS Pharmaceuticals, Inc..
“Effective as of the Transition Date, Russ Hawkinson has been appointed to serve as Silverback’s Interim Chief Financial Officer and principal financial officer.”
Jonathan Piazza was terminated as Chief Financial Officer at ARS Pharmaceuticals, Inc..
“On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022”
Valerie Odegard was terminated as President and Chief Scientific Officer at ARS Pharmaceuticals, Inc..
“On September 1, 2022, the board of directors of Silverback Therapeutics, Inc. (“Silverback”) approved the termination of employment of Valerie Odegard, Ph.D., our President and Chief Scientific Officer, and Jonathan Piazza, our Chief Financial Officer, effective as of September 2, 2022”
Thilo Schroeder departed as Director at ARS Pharmaceuticals, Inc..
“On March 11, 2022, Thilo Schroeder, Ph.D. informed Silverback Therapeutics, Inc. (the “Company”) that he will not stand for re-election as a member of the Company’s board of directors when his term as a Class II director expires at the Company’s 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the Company (the “Audit Committee”) to focus on other endeavors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.